CXCR4 and neoplasm: Additionally, small molecule inhibitors targeting the tumor microenvironment, such as C-X-C chemokine receptor type 4 (CXCR4) antagonists or angiotensin II receptor blockers, have been demonstrated to enhance the infiltration and functional activity of CAR-Ts in the context of leukemia [106,109].